Credit Suisse Upgrades ResMed (RMD) to Outperform
More News related to RMD
- Notable Analyst Rating Changes 11/06: GE, CBS, HD/LOW, M Upgrade; ESLR, RMD, SUN Downgrade
- Morgan Stanley Downgrades ResMed (RMD) to Equalweight
- Jefferies & Co Downgrades ResMed (RMD) to Hold
- ResMed (RMD) Tops Q3 Views
- ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
More News related to Upgrades
- Highlights From SWHC Q2 Conference Call: First Qtr Reflected Results From Two Segments Under S&W Umbrella; Guides Below for Q3
- NASB Financial (NASB) Posts Q4 EPS of $0.77, Tops Views
- Highlights From Take-Two Interactive Softwares' (TTWO) Forecast Teleconference
- Saks (SKS) Restates Q3 EPS to $0.04, Up from $0.01
- Big Lots (BIG) Delivers With Strong Q3 Results and Guidance
Credit Suisse upgrades ResMed (NYSE: RMD) from Neutral to Outperform.
To see more analyst ratings on RMD Click Here.
ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
Related Categories
UpgradesStocks Mentioned
+0.48Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
